Published in Clin Biochem on April 10, 2009
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ (2010) 6.37
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int (2010) 3.36
Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43
Causal assessment of dietary acid load and bone disease: a systematic review & meta-analysis applying Hill's epidemiologic criteria for causality. Nutr J (2011) 1.41
Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol (2012) 1.25
The clinical utility of bone marker measurements in osteoporosis. J Transl Med (2013) 1.21
Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. Ann Lab Med (2012) 1.17
Higher serum uric acid is associated with higher bone mass, lower bone turnover, and lower prevalence of vertebral fracture in healthy postmenopausal women. Osteoporos Int (2013) 1.14
Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. Osteoporos Int (2012) 0.90
Reference intervals of bone turnover markers determined by using their curve-fitting valley for adult females in China. Osteoporos Int (2013) 0.88
Improved nutritional status and bone health after diet-induced weight loss in sedentary osteoarthritis patients: a prospective cohort study. Eur J Clin Nutr (2011) 0.87
Are we taking full advantage of the growing number of pharmacological treatment options for osteoporosis? Curr Opin Pharmacol (2014) 0.85
Establishing reference intervals for bone turnover markers in healthy postmenopausal women in a nonfasting state. Bonekey Rep (2014) 0.81
Socioeconomic status, race, and bone turnover in the Midlife in the US Study. Osteoporos Int (2011) 0.79
Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass. Osteoporos Int (2011) 0.78
A Trimodality Comparison of Volumetric Bone Imaging Technologies. Part II: 1-Yr Change, Long-Term Precision, and Least Significant Change. J Clin Densitom (2014) 0.78
Bone strength and management of postmenopausal fracture risk with antiresorptive therapies: considerations for women's health practice. Int J Womens Health (2016) 0.77
The effect of whole body vibration therapy on bone density in patients with thalassemia: a pilot study. Am J Hematol (2012) 0.76
"Vitamin D supplementation and bone health in adults with diabetic nephropathy: the protocol for a randomized controlled trial". BMC Endocr Disord (2014) 0.76
Assessment of health claims in the field of bone: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). Osteoporos Int (2011) 0.76
Functional investigation of bone implant viability using radiotracers in a new model of osteonecrosis. Clinics (Sao Paulo) (2016) 0.75
Standardising biochemical assessment of bone turnover in osteoporosis. Clin Biochem (2011) 0.75
Antiosteoporotic effect of orally administered yolk-derived peptides on bone mass in women. Food Sci Nutr (2014) 0.75
Assessment of vitamin D status and serum CrossLaps levels in adults with primary lactose malabsorption. Eur J Clin Nutr (2016) 0.75
The role of enteric hormone GLP-2 in the response of bone markers to a mixed meal in postmenopausal women with type 2 diabetes mellitus. Diabetol Metab Syndr (2015) 0.75
L-Carnitine, but not coenzyme Q10, enhances the anti-osteoporotic effect of atorvastatin in ovariectomized rats. J Zhejiang Univ Sci B (2016) 0.75
The utility of procollagen type 1 N-terminal propeptide for the bone status assessment in postmenopausal women. Bosn J Basic Med Sci (2013) 0.75
Applicability of in vitro-in vivo translation of cathepsin K inhibition from animal species to human with the use of free-drug hypothesis. Naunyn Schmiedebergs Arch Pharmacol (2017) 0.75
A biochemical approach for assessing cutoffs at the age thresholds of 14 and 18 years: a pilot study on the applicability of bone specific alkaline phosphatase on an Italian sample. Int J Legal Med (2016) 0.75
Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2011) 23.10
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ (2010) 6.37
Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med (2007) 4.68
Effect of nonpayment for preventable infections in U.S. hospitals. N Engl J Med (2012) 4.19
Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med (2007) 3.27
Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev (2005) 3.01
Trends in hip fracture rates in Canada. JAMA (2009) 2.95
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell (2008) 2.84
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res (2015) 2.74
Vitamin D insufficiency in a population of healthy western Canadians. CMAJ (2002) 2.73
Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ (2009) 2.64
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med (2007) 2.64
Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate. JAMA (2010) 2.61
Overview of the Alberta Kidney Disease Network. BMC Nephrol (2009) 2.58
Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2008) 2.57
A controlled trial to increase detection and treatment of osteoporosis in older patients with a wrist fracture. Ann Intern Med (2004) 2.48
Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab (2012) 2.41
Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res (2010) 2.37
Postmenopausal women with osteopenia have higher cortical porosity and thinner cortices at the distal radius and tibia than women with normal aBMD: an in vivo HR-pQCT study. J Bone Miner Res (2010) 2.34
The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol (2012) 2.24
Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong? J Bone Miner Res (2004) 2.15
Mesolimbic dopamine reward system hypersensitivity in individuals with psychopathic traits. Nat Neurosci (2010) 2.01
Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med (2011) 1.95
Varying conceptions of competence: an analysis of how health sciences educators define competence. Med Educ (2012) 1.94
Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2009) 1.90
Age-related patterns of trabecular and cortical bone loss differ between sexes and skeletal sites: a population-based HR-pQCT study. J Bone Miner Res (2011) 1.86
Low bone mineral density and fracture burden in postmenopausal women. CMAJ (2007) 1.81
Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med (2012) 1.80
Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2012) 1.79
Effective initiation of osteoporosis diagnosis and treatment for patients with a fragility fracture in an orthopaedic environment. J Bone Joint Surg Am (2006) 1.72
Vitamin D insufficiency in North America. J Nutr (2005) 1.70
Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy. J Rheumatol (2009) 1.70
Diagnosis and management of vertebral fractures in elderly adults. Am J Med (2002) 1.68
Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician (2014) 1.63
Use of a case manager to improve osteoporosis treatment after hip fracture: results of a randomized controlled trial. Arch Intern Med (2007) 1.63
Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res (2014) 1.62
Accurate molecular detection of non-small cell lung cancer metastases in mediastinal lymph nodes sampled by endoscopic ultrasound-guided needle aspiration. Chest (2005) 1.62
The risk of hip fractures in older individuals with diabetes: a population-based study. Diabetes Care (2007) 1.61
Effect of low-intensity pulsed ultrasound on the cartilage repair in people with mild to moderate knee osteoarthritis: a double-blinded, randomized, placebo-controlled pilot study. Arch Phys Med Rehabil (2012) 1.60
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab (2002) 1.59
Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada (summary). CMAJ (2010) 1.59
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom (2004) 1.59
A cluster randomized trial of an enhanced eGFR prompt in chronic kidney disease. Clin J Am Soc Nephrol (2012) 1.57
Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol (2008) 1.55
Meta-analysis of the quantity of calcium excretion associated with the net acid excretion of the modern diet under the acid-ash diet hypothesis. Am J Clin Nutr (2008) 1.55
WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. PLoS Genet (2012) 1.55
Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J Bone Joint Surg Am (2012) 1.54
Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res (2010) 1.54
Development and pilot testing of a decision aid for postmenopausal women with osteoporosis. Patient Educ Couns (2002) 1.53
Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev (2002) 1.53
A before-and-after study of fracture risk reporting and osteoporosis treatment initiation. Ann Intern Med (2010) 1.51
The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women. BMC Musculoskelet Disord (2002) 1.47
Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. Menopause (2013) 1.47
Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging (2007) 1.44
The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy. Eur Urol (2011) 1.43
Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J Am Coll Cardiol (2003) 1.42
Empirically based composite fracture prediction model from the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW). J Clin Endocrinol Metab (2014) 1.41
Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res (2006) 1.41
Causal assessment of dietary acid load and bone disease: a systematic review & meta-analysis applying Hill's epidemiologic criteria for causality. Nutr J (2011) 1.41
Use of nonsteroidal antiinflammatory drugs: is there a change in patient risk profile after withdrawal of rofecoxib? J Rheumatol (2010) 1.39
Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. J Clin Endocrinol Metab (2012) 1.38
Attitudes of women who are currently using or recently stopped estrogen replacement therapy with or without progestins: results of the AWARE survey. J Obstet Gynaecol Can (2004) 1.38
Position statement of the Canadian Society of Clinical Chemists and Canadian Association of Medical Biochemists on hemoglobin A1c measurement and reporting. Clin Biochem (2012) 1.38
Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. J Bone Miner Res (2010) 1.37
Multifaceted intervention to improve diagnosis and treatment of osteoporosis in patients with recent wrist fracture: a randomized controlled trial. CMAJ (2008) 1.35
Change in bone mineral density as a function of age in women and men and association with the use of antiresorptive agents. CMAJ (2008) 1.33
Do hip protectors decrease the risk of hip fracture in institutional and community-dwelling elderly? A systematic review and meta-analysis of randomized controlled trials. Osteoporos Int (2005) 1.31
Incidental vertebral fractures discovered with chest radiography in the emergency department: prevalence, recognition, and osteoporosis management in a cohort of elderly patients. Arch Intern Med (2005) 1.31
Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med (2004) 1.29
Clinical review: Effect of vitamin D3 supplementation on improving glucose homeostasis and preventing diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab (2014) 1.29
Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res (2012) 1.29
Changes to osteoporosis prevalence according to method of risk assessment. J Bone Miner Res (2007) 1.28
Canadian Aboriginal women have a higher prevalence of vitamin D deficiency than non-Aboriginal women despite similar dietary vitamin D intakes. J Nutr (2007) 1.27
Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord (2005) 1.27
Mutations in NOTCH2 in families with Hajdu-Cheney syndrome. Hum Mutat (2011) 1.25
Predicting fractures in an international cohort using risk factor algorithms without BMD. J Bone Miner Res (2011) 1.22
Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial. PLoS Med (2008) 1.20
Meta-analysis of the effect of the acid-ash hypothesis of osteoporosis on calcium balance. J Bone Miner Res (2009) 1.19
Association between change in BMD and fragility fracture in women and men. J Bone Miner Res (2009) 1.19